CR Double-Crane(600062.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
CR Double-Crane
600062.SH
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China.
2.805 T
600062.SHMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking83/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE14.11%B
    • Profit Margin15.15%A
    • Gross Margin59.03%B
  • Growth ScoreD
    • Revenue YoY-3.74%D
    • Net Profit YoY0.24%C
    • Total Assets YoY4.15%C
    • Net Assets YoY11.71%B
  • Cash ScoreD
    • Cash Flow Margin82.64%C
    • OCF YoY-3.74%D
  • Operating ScoreB
    • Turnover0.61B
  • Debt ScoreB
    • Gearing Ratio27.79%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CHINARES PHARMA introduces new product system for downstream customers under 1,4-Butanediamine

    AASTOCKS·
    HK
    03320
    -0.41%
    SH
    600062
    -1.21%
    SZ
    002886
    -1.92%
    AASTOCKS·
    HK
    03320
    -0.41%
    SH
    600062
    -1.21%
    SZ
    002886
    -1.92%

    Han Song, Deputy General Manager of China Resources Group, is under investigation

    Wallstreetcn·
    HK
    01313
    -1.53%
    HK
    00836
    -1.27%
    HK
    01109
    -1.36%
    Wallstreetcn·
    HK
    01313
    -1.53%
    HK
    00836
    -1.27%
    HK
    01109
    -1.36%

    CR Double-Crane: Some drugs are proposed to be selected for national centralized drug procurement

    Zhitong·
    SH
    600062
    -1.21%
    Zhitong·
    SH
    600062
    -1.21%

    CR Pharmaceutical: CR Double-Crane's net profit for the first three quarters is 1.388 billion yuan, a year-on-year decrease of 1.7%

    Zhitong·
    SH
    600062
    -1.21%
    Zhitong·
    SH
    600062
    -1.21%

    CR Double-Crane: The net profit for the third quarter was 374 million yuan, a year-on-year increase of 6.71%

    Zhitong·
    SH
    600062
    -1.21%
    Zhitong·
    SH
    600062
    -1.21%
    © 2026 Longbridge｜Disclaimer